BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 27520560)

  • 21. Identification of differentially expressed genes in pancreatic ductal adenocarcinoma and normal pancreatic tissues based on microarray datasets.
    Liu L; Wang S; Cen C; Peng S; Chen Y; Li X; Diao N; Li Q; Ma L; Han P
    Mol Med Rep; 2019 Aug; 20(2):1901-1914. PubMed ID: 31257501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.
    Wang WY; Hsu CC; Wang TY; Li CR; Hou YC; Chu JM; Lee CT; Liu MS; Su JJ; Jian KY; Huang SS; Jiang SS; Shan YS; Lin PW; Shen YY; Lee MT; Chan TS; Chang CC; Chen CH; Chang IS; Lee YL; Chen LT; Tsai KK
    Gastroenterology; 2013 Nov; 145(5):1110-20. PubMed ID: 23896173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
    Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
    World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis.
    You L; Wang J; Zhang F; Zhang J; Tao H; Zheng X; Hu Y
    Mol Med Rep; 2019 Jan; 19(1):441-451. PubMed ID: 30483731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.
    Zhou Z; Liu S; Zhang M; Zhou R; Liu J; Chang Y; Zhao Q
    Dig Dis Sci; 2017 Oct; 62(10):2790-2800. PubMed ID: 28815403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
    Noll EM; Eisen C; Stenzinger A; Espinet E; Muckenhuber A; Klein C; Vogel V; Klaus B; Nadler W; Rösli C; Lutz C; Kulke M; Engelhardt J; Zickgraf FM; Espinosa O; Schlesner M; Jiang X; Kopp-Schneider A; Neuhaus P; Bahra M; Sinn BV; Eils R; Giese NA; Hackert T; Strobel O; Werner J; Büchler MW; Weichert W; Trumpp A; Sprick MR
    Nat Med; 2016 Mar; 22(3):278-87. PubMed ID: 26855150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic cancer survival analysis defines a signature that predicts outcome.
    Raman P; Maddipati R; Lim KH; Tozeren A
    PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance and prospective molecular mechanism of C‑C motif chemokine receptors in patients with early‑stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy.
    Zhou X; Liao X; Wang X; Huang K; Yang C; Yu T; Liu J; Han C; Zhu G; Su H; Qin W; Han Q; Liu Z; Huang J; Gong Y; Ye X; Peng T
    Oncol Rep; 2019 Nov; 42(5):1856-1868. PubMed ID: 31432181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of molecular pathways in pancreatic ductal adenocarcinomas with a bioinformatics approach.
    Wang Y; Li Y
    Asian Pac J Cancer Prev; 2015; 16(6):2561-7. PubMed ID: 25824797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The relationship and clinicopathological significance of Numb,MDM2 and p53 expression in human pancreatic cancer].
    Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
    Zhonghua Wai Ke Za Zhi; 2014 Sep; 52(9):675-81. PubMed ID: 25410780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
    Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
    Front Immunol; 2021; 12():690056. PubMed ID: 34335594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.
    Stratford JK; Bentrem DJ; Anderson JM; Fan C; Volmar KA; Marron JS; Routh ED; Caskey LS; Samuel JC; Der CJ; Thorne LB; Calvo BF; Kim HJ; Talamonti MS; Iacobuzio-Donahue CA; Hollingsworth MA; Perou CM; Yeh JJ
    PLoS Med; 2010 Jul; 7(7):e1000307. PubMed ID: 20644708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and lncRNA BC008363 an independent prognostic factor in PDAC.
    Li J; Liu D; Hua R; Zhang J; Liu W; Huo Y; Cheng Y; Hong J; Sun Y
    Pancreatology; 2014; 14(5):385-90. PubMed ID: 25200694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of long non-coding RNA LOC285194 and its prognostic significance in human pancreatic ductal adenocarcinoma.
    Ding YC; Yu W; Ma C; Wang Q; Huang CS; Huang T
    Int J Clin Exp Pathol; 2014; 7(11):8065-70. PubMed ID: 25550852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma.
    Birnbaum DJ; Begg SKS; Finetti P; Vanderburg C; Kulkarni AS; Neyaz A; Hank T; Tai E; Deshpande V; Bertucci F; Birnbaum D; Lillemoe KD; Warshaw AL; Mino-Kenudson M; Fernandez-Del Castillo C; Ting DT; Liss AS
    Clin Cancer Res; 2021 Apr; 27(8):2314-2325. PubMed ID: 33547202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer.
    Zhou M; Diao Z; Yue X; Chen Y; Zhao H; Cheng L; Sun J
    Oncotarget; 2016 Aug; 7(35):56383-56394. PubMed ID: 27487139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
    Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z
    Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
    Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
    J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
    Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
    Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data.
    Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB
    DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.